In June 2007，Sichuan Clover was established as a research laboratory.
In December 2011，We completed the Angel Round Investment and raised RMB10 million.
In November 2015，Sichuan Clover completed IND filing for SCB-808.
In December 2015，Sichuan Clover initiated GLP studies on at the National Shanghai Center for New Drug Safety Evaluation and Research.
In January 2016，Sichuan Clover commenced research on HIV subunit vaccine.
In July 2016，Sichuan Clover entered into an agreement to establish and build 32,000 sqm commercial-scale cGMP biomanufacturing facility in Changxing, Zhejiang Province, China.
In December 2017，We completed the Series A Investment and raised approximately RMB62.8 million.
In June 2018，Our first patient was dosed with SCB-313 for treatment of cancer patients with malignant ascites in Phase 1 clinical trial.
In November 2019，We completed the Series B Investment and raised approximately RMB304.1 million.
In January 2020，we initiated development of SCB-2019, our COVID-19 vaccine candidate.
In April 2020，We established a collaboration and received funding from CEPI for SCB-2019.
In June 2020，We completed the Series B-2 Investment and raised approximately RMB171.8 million.
In June 2020，Our first participant was dosed with SCB-2019 (CpG 1018/Alum) in Phase I clinical trial.
In November 2020，CEPI expanded our partnership and increased funding up to $328 million for SCB-2019 development through licensure.
In December 2020，We announced positive Phase 1 data for SCB-2019 (CpG 1018/Alum), our COVID-19 vaccine candidates.
In February 2021，We completed the Series C financing raising approximately US$230 million.
In March 2021，We initiated SPECTRA, a pivotal global Phase 2/3 clinical trial evaluating SCB 2019 (CpG 1018/Alum) for vaccine efficacy and dosed the first participant at a clinical trial site located in the Philippines.